--- title: "Alkermes anticipates record proprietary product sales above $1B for 2025 as orexin pipeline advances" description: "Alkermes plc anticipates record proprietary product sales exceeding $1 billion for 2025, driven by strong Q2 performance and advancements in its orexin pipeline. CEO Richard F. Pops highlighted sustai" type: "news" locale: "en" url: "https://longbridge.com/en/news/250649067.md" published_at: "2025-07-29T19:01:27.000Z" --- # Alkermes anticipates record proprietary product sales above $1B for 2025 as orexin pipeline advances > Alkermes plc anticipates record proprietary product sales exceeding $1 billion for 2025, driven by strong Q2 performance and advancements in its orexin pipeline. CEO Richard F. Pops highlighted sustained profitability, no debt, and over $1 billion in cash. Q2 revenues reached $390.7 million, with proprietary product net sales of $307.2 million, reflecting 14% year-over-year growth. The company is on track to meet or exceed its financial guidance, with expectations for continued growth in proprietary product sales. Analysts expressed cautious optimism regarding safety and regulatory pathways for alixorexton, while management remained confident in its data and product efficacy. Earnings Call Insights: Alkermes plc (ALKS) Q2 2025 Management View Richard F. Pops, CEO, described the quarter as "very successful" and highlighted "strong commercial and financial performance" with Alkermes "on track to deliver on our key objectives across the business" for 2025. He stated, "With sustained profitability now, no debt and more than... ### Related Stocks - [ALKS.US - Alkermes](https://longbridge.com/en/quote/ALKS.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 爱尔兰法院批准阿尔凯默斯收购 Avadel 制药公司 | 爱尔兰高等法院已批准 Alkermes plc 收购 Avadel Pharmaceuticals plc。法院未作修改地批准了该安排，允许 Alkermes 收购 Avadel 所有已发行的普通股。该交易仍需满足某些条件，且两家公司警告称 | [Link](https://longbridge.com/en/news/275510100.md) | | 阿尔凯默斯的执行副总裁兼研发负责人以及首席医疗官 Craig C. Hopkinson 报告了普通股的出售 | 阿尔凯默斯（Alkermes plc）研发执行副总裁兼首席医学官 Craig C. Hopkinson 报告了该公司普通股的处置。完整的文件可通过提供的链接获取。此新闻简报由公共技术公司生成，仅供信息参考，不应被视为财务、投资或法律建议。阿 | [Link](https://longbridge.com/en/news/271991860.md) | | 阿尔凯默斯看好 100 亿美元的睡眠市场，ALKS 2680 即将进入第三阶段，Avidel 交易即将完成 | 阿尔凯默斯（NASDAQ: ALKS）在摩根大通医疗健康大会上进行了演讲，强调了其在进入 2026 年时强大的增长基础。该公司正在推进其食欲素 2 受体激动剂候选药物 ALKS 2680，进入针对嗜睡症和特发性过度嗜睡的第三阶段测试，市场机 | [Link](https://longbridge.com/en/news/272469823.md) | | 阿尔凯默斯执行副总裁兼研发和首席医疗官 Craig C. Hopkinson 报告了普通股的出售 | Alkermes plc 的研发执行副总裁兼首席医学官 Craig C. Hopkinson 报告了该公司普通股的处置。完整的文件可以通过提供的链接访问。此新闻简报由公共技术生成，仅供信息参考，不应被视为财务、投资或法律建议。Alkerme | [Link](https://longbridge.com/en/news/271362738.md) | | FDA 授予阿尔凯默斯的 Alixorexton 用于 1 型嗜睡症的突破性疗法认定 | 阿尔凯默斯（Alkermes plc）已获得 FDA 对其研究药物 alixorexton 的突破性疗法认定，该药物旨在治疗 1 型嗜睡症。此项认定是在 1 期和 2 期临床试验取得积极结果后获得的，包括 Vibrance-1 研究，该研究 | [Link](https://longbridge.com/en/news/271647276.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.